Biovail Dodges Antitrust Class Actions Over Tiazac

Law360, New York (July 25, 2008, 12:00 AM EDT) -- An appeals court has rejected four antitrust class actions by wholesale drug purchasers claiming that Biovail Inc. violated antitrust laws by using patent litigation to keep Andrx Pharmaceuticals Inc. from making a generic version of its hypertension drug Tiazac, thereby affirming a district court decision.

Judge Douglas H. Ginsburg, writing for a three-judge panel of the U.S. Court of Appeals for the District of Columbia, said in an opinion on Friday that the plaintiffs had failed to make a case that Andrx could have begun marketing...
To view the full article, register now.